Dosage and usage of intravenous human immunoglobulin (Yimmugo)

Intravenous human immunoglobulin (Yimmugo) is an important immunotherapy drug, mainly used to treat diseases such as primary humoral immunodeficiency (PI). Its dosage and usage are key factors to ensure the therapeutic effect and patient safety. Depending on the indication, the recommended dose of intravenous human immunoglobulin is usually 300-800 mg/kg (i.e. 3-8 ml/kg), administered intravenously every 3 to 4 weeks. However, the specific dosage and dosage regimen need to be individually adjusted based on the patient's clinical response and body weight. Especially for underweight or overweight patients, careful calculation and dosage adjustment are required.

In practical applications, medication management is also crucial. Before starting an infusion, it is important to ensure that the patient is adequately hydrated to reduce the burden on the kidneys and reduce the risk of adverse effects. Yimmugo should be used via the intravenous route at or near body temperature, and avoid mixing with any other intravenous medications to prevent unnecessary drug interactions. During the infusion process, medical staff need to closely monitor the patient's vital signs, including heart rate, blood pressure, and respiratory rate, in order to detect potential adverse reactions in a timely manner

If adverse reactions, such as allergic reactions or other uncomfortable symptoms, occur during the infusion process, the infusion should be slowed down or stopped immediately, and the patient should be treated accordingly. If symptoms resolve rapidly, consider continuing the infusion at a comfortable lower rate. At the same time, for patients with existing renal insufficiency, special attention needs to be paid to preventing volume failure. Therefore, in such patients, the lowest infusion rate is recommended to ensure safety.

Those patients judged to be at risk for renal dysfunction or thrombosis also need to be administered at the lowest practicable infusion rate and have renal function assessed periodically after infusion. If a patient's renal function is found to worsen, discontinuation of dosing should be considered to avoid further risks.

Reference materials:https://www.rxlist.com/yimmugo-drug.htm